Drugs / CD19/22 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04539444 | Aug 2020 → Sep 2022 | non-Hodgkin lymphoma | The First Affiliated Hospital of Soochow University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/22 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04539444 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T cells (CART) therapy” NCT04539444 ↗ |
| Target | CD19 | “CD19/22 CART cells are administrated in a 3-day split-dose regimen at dose of 0.5- 2×10\*107 CART cells per kilogram of body weight.” NCT04539444 ↗ |